Trial Profile
A trial of brentuximab vedotin for the treatment of patients with relapsed/refractory hodgkin lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2016
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 27 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology